QRG Capital Management Inc. raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,816 shares of the company's stock after buying an additional 7,306 shares during the period. QRG Capital Management Inc.'s holdings in Sanofi were worth $8,364,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. Bessemer Group Inc. grew its position in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi in the fourth quarter worth $31,000. Sierra Ocean LLC bought a new stake in shares of Sanofi during the fourth quarter worth $44,000. UMB Bank n.a. increased its stake in shares of Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after buying an additional 264 shares in the last quarter. Finally, Whipplewood Advisors LLC bought a new position in shares of Sanofi in the fourth quarter valued at about $76,000. Institutional investors and hedge funds own 14.04% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on SNY shares. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Finally, Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $61.50.
Check Out Our Latest Research Report on Sanofi
Sanofi Trading Down 1.2%
SNY stock traded down $0.60 during midday trading on Thursday, reaching $47.62. The company's stock had a trading volume of 2,782,958 shares, compared to its average volume of 2,377,740. The business's 50-day simple moving average is $51.35 and its 200-day simple moving average is $52.01. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The stock has a market cap of $116.79 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 0.98 and a beta of 0.50.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm's revenue was down 11.0% on a year-over-year basis. During the same period last year, the company earned $1.78 EPS. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The business also recently announced an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a dividend of $2.0369 per share. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date was Friday, May 9th. Sanofi's payout ratio is presently 57.14%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
